Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Merck’s Covid-19 push narrows further
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Blood clot fears spread to J&J’s Covid-19 vaccine
The US pauses use of JNJ-78436735 after six cases of cerebral venous sinus thrombosis.
Delays look like the best-case scenario for teplizumab
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Fibrogen stretches the bounds of credibility
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
